Complication of transoral robotic surgery: single institution study
10.3760/cma.j.cn115330-20240423-00227
- VernacularTitle:经口机器人手术并发症总结
- Author:
Haitao XIAO
1
;
Yabing ZHANG
;
Xiaoyan YUAN
;
Bin ZHANG
Author Information
1. 北京和睦家医院普外科，北京 100015
- Publication Type:Journal Article
- Keywords:
Head and neck neoplasms;
Transoral robotic surgery;
Complications
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2025;60(3):300-304
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the complications of transoral robotic surgery (TORS) and to identify the risk factors for the complications.Methods:This was a retrospective study of 134 cases of head and neck tumors underwent TORS at the Department of Surgery of Beijing United Family Hospital from September 2017 to June 2024. There were 9 cases of benign tumors and 125 cases of malignant tumors, including 119 squamous cell carcinomas, 3 adenocarcinomas, 2 lymphomas, and 1 sarcoma. There were 37 cases of pure TORS and 96 cases of TORS combined with neck dissection. Postoperative complications within 90 days were collected and graded with the Clavien-Dindo system. χ2 test was used for statistical analysis. Results:A total of 25 (18.7%) cases experienced surgical complications, including 9 cases with Clavien-Dindo grade≥Ⅲ complications. Postoperative complications included 2 cases of death, 3 cases of massive hemorrhage, 3 cases of pharyngeal fistula, 2 cases of aspiration pneumonia, 2 cases of minor bleeding, 1 case of tooth injury, 1 case of arytenoid dislocation, 2 cases of tongue laceration, and 10 cases of long-term (>3 months) tracheostomy open. Postoperative pharyngeal fistula was significantly correlated with the scope of neck dissection ( χ2=9.86, P<0.05), and Clavien-Dindo grade≥Ⅲ complications were significantly correlated with the scope of neck dissection ( χ2=13.91, P<0.05) and tumor N stage ( χ2=14.33, P<0.05). Conclusion:The high N-stage and neck dissection involving more than three regions are risk factors for the complications of TORS for head and neck tumors.
